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Apart from drug resistance, the patients’ oversensitivity to
chemotherapy is one of the most serious problems in
cancer treatment. Cytotoxic drugs aim the intensively pro-
liferating cancer cells, but unfortunately these drugs also
destroy other cells and tissues with high proliferation
rates, such as epithelia in gastro-intestinal track and cells
in the bone marrow and skin, leading to chemotherapy-
related toxicities. Furthermore, these adverse reactions are
also observed in relatively slow proliferating tissues in
organs involved in systemic detoxification and clearance, i.
e. in liver and kidneys.
The most common breast cancer chemotherapy regime
is FAC, which combines 5-fluorouracil, doxorubicin and
cyclophosphamide. These drugs on the cellular level are
responsible for genetic material damage leading to cell
cycle checkpoints activation and cell death. Because of the
complexity of cellular pathways of each FAC drug, it is
expected that molecular mechanisms causing development
of adverse reactions to these three drugs are very complex.
Relationships between genetic polymorphisms and
chemotherapy-induced toxicity were analyzed in group of
200 breast cancer patients treated with FAC regime in
first-line chemotherapy. 13 genetic modifications were
selected for this study, including functional variants in
genes encoding proteins involved in FAC drugs transport
(ABCB1, ABCC2, ABCG2), metabolism (CYP2C19,
GSTT1, GSTM1, GSTP1, TYMS, MTHFR) and drug-
induced damage repair (ERCC1, ERCC2, XRCC1).
Multifactorial pharmacogenetic models were possible to
establish for treatment-related overall and early anemia
(low hemoglobin as well as anisocytosis), hepatotoxicity
and gastro-intestinal symptoms (nausea). Genetic variants
responsible for high risk of these toxicities belonged to
transport and metabolic pathways of all three FAC drugs,
which confirm the complex causative network of factors
underlining systemic adverse reaction to treatment.
Furthermore, accumulation of the unfavorable genotypes
was responsible for drastic increase of toxicity risk- OR
8.29 and 31.5 for, respectively, overall and early anemia,
OR 4.36 and 8.36 for overall and early anisocytosis, OR
7.63 for overall hepatotoxicity and OR 3.07 for early
nausea. Potentially life-threatening severe neutropenia
correlated with only one genetic polymorphism, but none-
theless we observed over twofold increase in toxicity risk
for common allele of VNTR variant in TYMS gene.
The results suggest that accumulated modifications in
transport, metabolic and damage repair FAC drugs path-
ways are strongly responsible for systemic unfavorable
reaction to treatment. It is believed, that comprehensive
model consisting of many genetic alterations could make a
promising potential predictive tool of treatment-related
toxicity for the 5-fluorouracil, doxorubicin and cyclopho-
sphamide-treated breast cancer patients.
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